Organon & Co. (NYSE:OGN) Stock Position Lessened by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC trimmed its holdings in shares of Organon & Co. (NYSE:OGN - Free Report) by 37.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,019 shares of the company's stock after selling 23,621 shares during the period. Nisa Investment Advisors LLC's holdings in Organon & Co. were worth $597,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in OGN. Prospera Private Wealth LLC purchased a new position in Organon & Co. in the 3rd quarter worth approximately $25,000. Horizon Bancorp Inc. IN lifted its position in shares of Organon & Co. by 2,401.5% during the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company's stock worth $25,000 after purchasing an additional 1,585 shares in the last quarter. William B. Walkup & Associates Inc. purchased a new position in shares of Organon & Co. in the second quarter valued at $31,000. Versant Capital Management Inc increased its stake in Organon & Co. by 92.2% during the 4th quarter. Versant Capital Management Inc now owns 2,760 shares of the company's stock worth $41,000 after buying an additional 1,324 shares during the period. Finally, MassMutual Private Wealth & Trust FSB lifted its holdings in Organon & Co. by 32.4% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company's stock worth $41,000 after buying an additional 672 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, TD Cowen upgraded Organon & Co. to a "hold" rating in a research note on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $21.33.

Organon & Co. Stock Down 1.3 %

Shares of NYSE:OGN traded down $0.22 during midday trading on Wednesday, reaching $15.85. The company had a trading volume of 1,659,006 shares, compared to its average volume of 2,586,911. The stock has a market capitalization of $4.08 billion, a P/E ratio of 3.14, a PEG ratio of 0.87 and a beta of 0.76. The stock's fifty day moving average price is $15.42 and its 200-day moving average price is $18.00. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. Organon & Co. has a one year low of $13.87 and a one year high of $23.10.

Organon & Co. (NYSE:OGN - Get Free Report) last released its earnings results on Thursday, October 31st. The company reported $0.87 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.03). The company had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. Organon & Co.'s revenue for the quarter was up 4.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.78 EPS. Equities research analysts expect that Organon & Co. will post 3.82 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Shareholders of record on Tuesday, November 12th were paid a dividend of $0.28 per share. The ex-dividend date was Tuesday, November 12th. This represents a $1.12 annualized dividend and a yield of 7.07%. Organon & Co.'s payout ratio is 22.22%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.